Boston Scientific Announces Investor Event for Key Clinical Data Discussion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2026
0mins
Should l Buy BSX?
Source: PRnewswire
- Investor Event Announcement: Boston Scientific will host an investor event on March 28, 2026, at 6:30 PM ET to discuss key clinical data presented at the 75th Annual Scientific Session of the American College of Cardiology, aiming to enhance investor understanding and confidence in the company's innovative medical technologies.
- Executive Hosts: The event will be co-hosted by Dr. Kenneth Stein, Senior Vice President and Global Chief Medical Officer, Dr. Brad Sutton, Chief Medical Officer for AF Solutions, and Dr. Michael R. Jaff, Vice President and Chief Medical Officer for Vascular Therapies, ensuring a high level of expertise and authority.
- Live Webcast and Replay: The event will be available via live webcast, with a replay accessible approximately one hour after the event's conclusion, facilitating information access for investors unable to attend live, thereby enhancing communication and transparency between the company and its investors.
- Company Background: Boston Scientific has over 45 years of experience in the medical technology field, committed to transforming lives through innovative technologies that improve patient health, offering a broad range of high-performance solutions to address unmet patient needs and reduce healthcare costs, showcasing its leadership in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 56.500
Low
94.00
Averages
108.14
High
132.00
Current: 56.500
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific to Participate in Strategic Decisions Conference
- Conference Participation: Boston Scientific will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 27, 2026, with CEO Mike Mahoney and CMO Janar Sathananthan engaging in a 50-minute Q&A session, which is expected to enhance investor understanding of the company's strategy.
- Earnings Call: The company will host a conference call on July 29, 2026, at 8:00 AM ET to discuss financial results and business highlights for the second quarter ended June 30, thereby increasing transparency and attracting investor interest.
- Financial Results Announcement: Boston Scientific will issue a news release announcing its second-quarter 2026 financial results prior to the earnings call, ensuring that investors receive timely key information that could influence market expectations regarding the company's future performance.
- Webcast Availability: Live webcasts and replays of each event will be accessible on the company's investor website, enhancing information accessibility and ensuring that investors can stay updated on the latest company developments.
See More
Market Recovers but Growth Stocks Struggle
- ServiceNow Performance Review: Despite achieving a 20% revenue growth in 2022 and a 19% growth in Q1 2023, ServiceNow's stock has plummeted over 50% from its July peak, reflecting an overreaction from the market towards AI stocks, resulting in a three-year low market cap.
- Roblox Growth Slowdown: The recently implemented age verification measures have led Roblox to revise its 2023 revenue growth forecast down from 23%-29% to 20%-25%, even though last quarter's revenue reached $1.4 billion, a 39% increase, indicating short-term market pressures.
- Boston Scientific Outlook Adjustment: Boston Scientific's Watchman implant showed promising results in trials, but the unclear long-term benefits have caused a reduction in its 2026 revenue growth forecast from 10%-11% to 6.5%-8%, although analysts remain optimistic, viewing the current stock price as a buying opportunity.
- Market Sentiment Analysis: Following a strong rebound in April, the overall market has seen certain growth stocks suffer due to fluctuating market sentiment, prompting investors to carefully assess the long-term value versus short-term volatility of these stocks.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading to investor losses when the company missed net income expectations for the first quarter, revealing management's concealment of unsustainable growth in its electrophysiology segment.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
- Investor Selection Advice: Investors are advised to be cautious when selecting legal counsel, avoiding inexperienced intermediaries, and ensuring that their chosen law firm has the capability to handle securities class actions to maximize potential recovery opportunities.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, with plaintiffs being investors who purchased securities between July 23, 2025, and February 3, 2026, seeking to recover damages.
- False Statement Allegations: The complaint alleges that the company made materially false and misleading statements during the relevant period, failing to disclose that the projected growth rate for its U.S. electrophysiology segment was unsustainable, which undermined investor confidence in the company's future.
- Market Reaction: Plaintiffs claim that management's optimistic outlook for the U.S. electrophysiology division lacked a reasonable basis and failed to timely disclose competitive pressures and regulatory challenges, potentially leading to significant investor losses.
- Investor Action: Affected investors have until May 4, 2026, to request to be appointed as lead plaintiffs, and Boston Scientific investors need not worry about litigation costs, as attorney fees are typically reimbursed by the court only upon success.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the Class Period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company's net income fell short of expectations.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its success and resource advantages in handling such cases.
- Investor Selection Advice: Investors are advised to carefully choose legal counsel and avoid working with inexperienced middlemen to ensure effective legal representation in the class action.
See More
Boston Scientific Securities Litigation Reminder
- Legal Action Notification: Faruq & Faruq LLP is investigating potential claims against Boston Scientific Corporation, particularly for investors who purchased or acquired securities between July 23, 2025, and February 3, 2026.
- Investor Rights Protection: The firm encourages affected investors to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action is May 4, 2026, urging timely action to protect their rights.
- Potential Impact Assessment: This litigation could negatively affect Boston Scientific's stock price and market reputation, prompting investors to closely monitor developments to make informed investment decisions.
See More
Boston Scientific to Participate in Strategic Decisions Conference
- Conference Participation: Boston Scientific will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 27, 2026, with CEO Mike Mahoney and CMO Janar Sathananthan engaging in a 50-minute Q&A session, which is expected to enhance investor understanding of the company's strategy.
- Earnings Call: The company will host a conference call on July 29, 2026, at 8:00 AM ET to discuss financial results and business highlights for the second quarter ended June 30, thereby increasing transparency and attracting investor interest.
- Financial Results Announcement: Boston Scientific will issue a news release announcing its second-quarter 2026 financial results prior to the earnings call, ensuring that investors receive timely key information that could influence market expectations regarding the company's future performance.
- Webcast Availability: Live webcasts and replays of each event will be accessible on the company's investor website, enhancing information accessibility and ensuring that investors can stay updated on the latest company developments.
See More
Market Recovers but Growth Stocks Struggle
- ServiceNow Performance Review: Despite achieving a 20% revenue growth in 2022 and a 19% growth in Q1 2023, ServiceNow's stock has plummeted over 50% from its July peak, reflecting an overreaction from the market towards AI stocks, resulting in a three-year low market cap.
- Roblox Growth Slowdown: The recently implemented age verification measures have led Roblox to revise its 2023 revenue growth forecast down from 23%-29% to 20%-25%, even though last quarter's revenue reached $1.4 billion, a 39% increase, indicating short-term market pressures.
- Boston Scientific Outlook Adjustment: Boston Scientific's Watchman implant showed promising results in trials, but the unclear long-term benefits have caused a reduction in its 2026 revenue growth forecast from 10%-11% to 6.5%-8%, although analysts remain optimistic, viewing the current stock price as a buying opportunity.
- Market Sentiment Analysis: Following a strong rebound in April, the overall market has seen certain growth stocks suffer due to fluctuating market sentiment, prompting investors to carefully assess the long-term value versus short-term volatility of these stocks.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading to investor losses when the company missed net income expectations for the first quarter, revealing management's concealment of unsustainable growth in its electrophysiology segment.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
- Investor Selection Advice: Investors are advised to be cautious when selecting legal counsel, avoiding inexperienced intermediaries, and ensuring that their chosen law firm has the capability to handle securities class actions to maximize potential recovery opportunities.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation is facing a class action lawsuit for alleged violations of federal securities laws, with plaintiffs being investors who purchased securities between July 23, 2025, and February 3, 2026, seeking to recover damages.
- False Statement Allegations: The complaint alleges that the company made materially false and misleading statements during the relevant period, failing to disclose that the projected growth rate for its U.S. electrophysiology segment was unsustainable, which undermined investor confidence in the company's future.
- Market Reaction: Plaintiffs claim that management's optimistic outlook for the U.S. electrophysiology division lacked a reasonable basis and failed to timely disclose competitive pressures and regulatory challenges, potentially leading to significant investor losses.
- Investor Action: Affected investors have until May 4, 2026, to request to be appointed as lead plaintiffs, and Boston Scientific investors need not worry about litigation costs, as attorney fees are typically reimbursed by the court only upon success.
See More
Boston Scientific Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the Class Period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company's net income fell short of expectations.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its success and resource advantages in handling such cases.
- Investor Selection Advice: Investors are advised to carefully choose legal counsel and avoid working with inexperienced middlemen to ensure effective legal representation in the class action.
See More
Boston Scientific Securities Litigation Reminder
- Legal Action Notification: Faruq & Faruq LLP is investigating potential claims against Boston Scientific Corporation, particularly for investors who purchased or acquired securities between July 23, 2025, and February 3, 2026.
- Investor Rights Protection: The firm encourages affected investors to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action is May 4, 2026, urging timely action to protect their rights.
- Potential Impact Assessment: This litigation could negatively affect Boston Scientific's stock price and market reputation, prompting investors to closely monitor developments to make informed investment decisions.
See More
